Related Experiment Video
Updated: May 1, 2026
08:04
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
12.2K
PDGF/PDGFR effects in osteosarcoma and the "add-on" strategy
Clinical Sarcoma Research
|August 8, 2018
Summary
Targeting the platelet-derived growth factor (PDGF)/platelet-derived growth factor receptor (PDGFR) pathway shows promise for osteosarcoma. Combining PDGF/PDGFR inhibitors with other treatments may improve patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Advanced osteosarcoma treatment options are limited.
- The platelet-derived growth factor (PDGF)/platelet-derived growth factor receptor (PDGFR) pathway is implicated in osteosarcoma development and metastasis.
- This pathway influences tumor angiogenesis and interstitial fluid pressure.
Purpose of the Study:
- To explore the potential of targeting the PDGF/PDGFR pathway in osteosarcoma treatment.
- To investigate the efficacy of PDGF/PDGFR inhibitors, particularly in combination therapy.
Main Methods:
- Review of existing literature on PDGF/PDGFR pathway in osteosarcoma.
- Analysis of clinical trial outcomes for PDGF/PDGFR inhibitors in sarcoma.
Main Results:
- Single-agent PDGF/PDGFR inhibitors showed disappointing results in osteosarcoma and soft tissue sarcoma.
- Combination therapy (add-on strategy) demonstrated a synergistic antitumor effect in soft tissue sarcoma.
Conclusions:
- Targeting the PDGF/PDGFR pathway is a promising strategy for osteosarcoma.
- Further investigation into combination therapies involving PDGF/PDGFR inhibitors is warranted for osteosarcoma treatment.
